

Oncology Pipeline



The oncology portfolio of Daiichi Sankyo is powered by our team of world-class scientists that push beyond traditional thinking to create transformative medicines for people with cancer. We also work alongside leading academic and business collaborators to further advance the understanding of cancer as Daiichi Sankyo builds towards our ambitious goal of becoming a global leader in oncology by 2025.

World-Class Science Organization

Daiichi Sankyo is committed to becoming a world-class science organization. Our team's exceptional scientific attitude results in outstanding medicinal chemistry, antibody engineering and discovery biology.

Sustainable and Dynamic R&D Engine

The oncology portfolio of Daiichi Sankyo is powered by our research engines:

- Biologics, medicinal chemistry, modality, and other research laboratories in Japan
- Plexxikon Inc. – our small molecule structure-guided R&D center in the U.S.

"3 and Alpha" R&D Strategy

Anchored by our DXd antibody drug conjugate (ADC) technology, our obligation is to harness the power of true innovation to discover and develop innovative first-in-class and best-in-class treatments that transform the standard of care for people with cancer.

Enhanced Capabilities Through Collaboration

To complement and expand our premier cadre of internal scientists, we are collaborating with leading academic and business partners to leverage cutting-edge science in new treatment modalities, disease biology and diagnostics:

RESEARCH & TECHNOLOGY



TRANSLATIONAL & DEVELOPMENT



Pipeline at a Glance

These are investigational medicines and have not been approved by regulatory agencies for the proposed indications in the regions listed below. Safety and efficacy for these indications has not yet been established.

3 Lead ADCs

Trastuzumab Deruxtecan (T-DXd)* | Target: HER2

*fam-trastuzumab deruxtecan-nxki in the U.S. only

Joint global development and commercialization agreement with AstraZeneca as of March 2019



STUDY NAME OR TUMOR TYPE	OVERVIEW	PHASE	CONTINENT
DESTINY-Breast09	HER2 Positive Breast Cancer 1L versus THP (taxane, trastuzumab and pertuzumab) with or without pertuzumab	Phase 3	Africa, Asia, Europe, North America, Oceania, South America
DESTINY-Breast08	HER2 Low Breast Cancer Chemotherapy Naïve /Post-Chemotherapy combination with capecitabine; durvalumab + paclitaxel; capivasertib; anastrozole; or fulvestrant	Phase 1b	Asia, North America, Oceania
DESTINY-Breast07	HER2 Positive Breast Cancer 2L/1L combination with durvalumab; pertuzumab; paclitaxel; or, durvalumab + paclitaxel	Phase 1b/2	Asia, Europe, North America, Oceania, South America
DESTINY-Breast06	HER2 Low/HR Positive Breast Cancer Chemotherapy Naïve versus physician's choice (capecitabine, paclitaxel or nab-paclitaxel)	Phase 3	Asia, Europe, North America, Oceania, South America
DESTINY-Breast05	HER2 Positive Residual Invasive Breast Cancer After Neoadjuvant Therapy versus trastuzumab emtansine (T-DM1)	Phase 3	Asia, Europe, North America, Oceania, South America
DESTINY-Breast04	HER2 Low Breast Cancer Post Chemotherapy versus physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel)	Phase 3	Asia, Europe, North America
DESTINY-Breast03	HER2 Positive Breast Cancer 2L versus trastuzumab emtansine (T-DM1)	Phase 3	Asia, Europe, North America, Oceania, South America
DESTINY-Breast02	HER2 Positive Breast Cancer 3L versus physician's choice (trastuzumab + capecitabine or lapatinib)	Phase 3	Asia, Europe, North America, Oceania, South America
BEGONIA	Triple Negative Breast Cancer combination with durvalumab	Phase 1b/2	Asia, Europe, North America
Breast/Non-Small Cell Lung Cancer	HER2 Positive Breast or Non-Small Cell Lung Cancer combination with pembrolizumab	Phase 1	Europe, North America
Breast/Bladder Cancer	HER2 Positive Breast or Bladder Cancer combination with nivolumab	Phase 1	Europe, North America
DESTINY-Gastric04	HER2 Positive Gastric Cancer 2L versus ramucirumab + paclitaxel	Phase 3	Asia, Europe
DESTINY-Gastric03	HER2 Positive Gastric Cancer 2L/1L Treatment Naïve / Post Chemotherapy combination with fluorouracil; capecitabine; durvalumab; oxaliplatin + fluorouracil or capecitabine; or, durvalumab + fluorouracil or capecitabine	Phase 1b/2	Asia, Europe, North America, South America
DESTINY-Gastric02	HER2 Positive Gastric Cancer 2L (monotherapy)	Phase 2	Europe, North America
DESTINY-Lung03	HER2 Positive Non-Small Cell Lung Cancer combination with durvalumab; durvalumab + cisplatin; durvalumab + carboplatin; durvalumab + pemetrexed	Phase 1b	Asia, Europe, North America
DESTINY-Lung02	HER2 Mutated Non-Small Cell Lung Cancer 2L+ (monotherapy)	Phase 2	Asia, Europe, North America, Oceania
DESTINY-Lung01	HER2+ or HER2 Mutated Non-Small Cell Lung Cancer 2L+ (monotherapy)	Phase 2	Asia, Europe, North America US Breakthrough Therapy Designation
HUDSON	Non-Small Cell Lung Cancer 2L+ combination with durvalumab	Phase 2	Asia, Europe, North America
DESTINY-CRC02	HER3 Overexpressing Colorectal Cancer 3L (monotherapy)	Phase 2	Asia, Europe, North America, Oceania
DESTINY-PanTumor02	HER2 Expressing Cancers (monotherapy)	Phase 2	Asia, Europe, North America, Oceania, South America
DESTINY-PanTumor01	HER2 Mutated Cancers (monotherapy)	Phase 2	Asia, Europe, North America

Datopotamab Deruxtecan (Dato-DXd) | Target: TROP2

Joint global development and commercialization agreement with AstraZeneca as of July 2020



STUDY NAME OR TUMOR TYPE	OVERVIEW	PHASE	CONTINENT
TROPION-Lung05	Non-Small Cell Lung Cancer with actionable genomic alterations (monotherapy)	Phase 2	Asia, Europe, North America
TROPION-Lung04	Non-Small Cell Lung Cancer without actionable genomic alterations combination with durvalumab with or without platinum chemotherapy	Phase 1	Asia, Europe, North America, Oceania
TROPION-Lung02	Non-Small Cell Lung Cancer without actionable genomic alterations combination with pembrolizumab with or without platinum chemotherapy	Phase 1	Asia, Europe, North America
TROPION-Lung01	Non-Small Cell Lung Cancer without genomic alterations versus docetaxel	Phase 3	Asia, Europe, North America, Oceania, South America
TROPION-PanTumor01	Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, HR Positive/HER2 Negative Breast Cancer, and Other Tumors (monotherapy)	Phase 1	Asia, North America
BEGONIA	Triple Negative Breast Cancer combination with durvalumab	Phase 1b/2	Asia, Europe, North America

Pipeline at a Glance (continued)

These are investigational medicines and have not been approved by regulatory agencies for the proposed indications in the regions listed below. Safety and efficacy for these indications has not yet been established.

3 Lead ADCs (continued)

Patritumab Deruxtecan (HER3-DXd) | Target: HER3



STUDY NAME OR TUMOR TYPE	OVERVIEW	PHASE	CONTINENT
HERTHENA-Lung01	EGFR Mutated Non-Small Cell Lung Cancer (monotherapy)	Phase 2	Asia, Europe, Oceania, North America
Non-Small Cell Lung Cancer	EGFR Mutated Non-Small Cell Lung Cancer combination with osimertinib	Phase 1	Asia, North America
Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer (monotherapy)	Phase 1	Asia, Europe, North America
Breast Cancer	HER3 Expressing Breast Cancer (monotherapy)	Phase 1/2	Asia, North America
Colorectal Cancer	Colorectal Cancer (monotherapy)	Phase 2	Asia, Europe, North America

Alpha

COMPOUND	TARGET	STUDY NAME OR TUMOR TYPE	PHASE	CONTINENT (Global Study) REGION (if Japan- or US-only development at this time)
Quizartinib QUANTUM-First	FLT3	FLT3-ITD Acute Myeloid Leukemia 1L	Phase 3	Asia, Europe, North America Orphan Drug Designation in US, Europe and Japan
Pexidartinib	CSF1R/KIT/ FLT3	Tenosynovial Giant Cell Tumor	Phase 3	China, Taiwan
		Tenosynovial Giant Cell Tumor	Phase 2	Japan
DS-1001	IDH1	IDH1 Mutated Glioma	Phase 2	Japan
		Adult T-Cell Leukemia/Lymphoma	Phase 2	Japan
Valemetostat	EZH1/2	Peripheral T-Cell Lymphoma including Adult T-Cell Leukemia/Lymphoma	Phase 2	Asia, Europe, North America SAKIGAKE Designation for Peripheral T-Cell Lymphoma
		Acute Myeloid Leukemia or Acute Lymphocytic Leukemia	Phase 1	US
		Non-Hodgkin's Lymphoma	Phase 1	Japan, US
PLX2853	BET	Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Phase 1b	US
		Prostate Cancer combination with abiraterone acetate and prednisone; and combination with olaparib	Phase 1b/2a	Europe, US
		Gynecologic Neoplasms or Ovarian Cancer	Phase 1b/2a	US
DS-1055	GARP	Solid Tumors	Phase 1b/2a	US
		Solid Tumors	Phase 1	Japan, US
DS-7300 (DXd-ADC) (Strategic collaboration with Sarah Cannon Research Institute)	B7-H3	Solid Tumors	Phase 1/2	Japan, US
DS-6157 (DXd-ADC) (Strategic collaboration with Sarah Cannon Research Institute)	GPR20	Gastrointestinal Stromal Tumor	Phase 1	Japan, US
DS-6000 (DXd-ADC) (Strategic collaboration with Sarah Cannon Research Institute)	CDH6	Renal Cell Carcinoma and Ovarian Cancer	Phase 1	US
DS-3939 (DXd-ADC)	TA-MUC1	Solid Tumor	Preclinical	